The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to collect urine samples from patients with fibrodysplasia ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease progression and for prediction of flare-ups of the disease. Disease related biomarkers in these patients are currently unknown. This study aims to support the development of novel therapy/ies for this disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
5 Years to 35 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with Fibrodysplasia Ossificans Progressiva.
Male and female patients ≥ 5 and ≤ 35 years of age with a diagnosis of FOP.
Physically able to provide first-morning urine sample of at least 30 mL
Able to communicate well with the investigator, to understand and comply with the requirements of the study
About half of the patients enrolled should have a flare-up, which is defined as an acute exacerbation of disease activity characterized by two or more of the following symptoms: pain, swelling, decreased range of motion, impaired function
Diagnosis of diabetes
Diagnosis of other systemic inflammatory disorder (juvenile idiopathic arthritis, systemic lupus erythematosus, etc.)
Diagnosis of cancer other than nonmelanomatous skin cancer.